Navigation Links
Valensa International's Dr. Rudi E. Moerck Appointed CEO
Date:2/19/2009

Pharmaceutical Industry Veteran Will Lead Company in Development of 'Next Generation' Dietary Supplements and Functional Food Ingredients

ORLANDO, Fla., Feb. 19 /PRNewswire/ -- Valensa International has appointed Dr. Rudi E. Moerck as President & Chief Executive Officer of the company. The move to add CEO duties for Dr. Moerck comes on the heels of Valensa's partnership with Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd, Chennai, India) announced last November. In a career that spans more than 25 years, Dr. Moerck has held senior management positions in the pharmaceutical and specialty chemical industries, as well as research and commercial development positions. In his new role, Dr. Moerck will lead Valensa's move into the next generation of high-performance plant-derived dietary supplements and functional food ingredients, which includes Valensa's "Direct to Marketers" product development and business strategy. He will lead Valensa's new management team that includes executives from both Valensa and Parry.

According to Dr. Moerck, the market opportunities for dietary supplements and functional food ingredients are greater than they have ever been. "Health and well-being have become lifestyle decisions for a rapidly growing population segment in the United States and worldwide. A focus on staying healthy and preventing the chronic illnesses that have become so common in our society is a part of emerging healthcare strategies. Simultaneously, the desire for natural products is still increasing throughout all age, income and gender demographics," he said. "We feel that our strategy at Valensa -- to use the most scientifically important natural materials, to use the best technology and quality control, to optimize the product forms in terms of stability and efficacy, and to create compelling messages around our products -- will position us as a 'next generation' leader to the industry and the consumer."

In his previous two years as President, Moerck positioned Valensa as the industry's leading US-based astaxanthin oleoresin and beadlet producer. Moerck also spearheaded Valensa's technology development effort aimed at increasing the bioavailability and efficacy of natural compounds via extraction optimization, dispersion and stabilization technologies and through optimized synergistic ingredient combinations. Under Moerck, Valensa also expanded their intellectual property position with US Patents for USPlus(R) saw palmetto prostate formulas, including Certified Organic USPlus(R), and Zanthin(R) astaxanthin for use in eye health.

Prior to joining Valensa, Dr. Moerck was President of Altair Nanotechnologies. While at Altair, he was the principal inventor of RenaZorb(TM). RenaZorb(TM) was in-licensed by Spectrum Pharmaceuticals (Irvine, CA) in January 2005. While at Altair, he was also the chief innovator of a new drug delivery system called TiNano Spheres(TM) for enhanced and timed release of pharmaceuticals. His work in the pharmaceutical industry includes postings at Catalytica Pharmaceuticals as Sr. Vice President Sales and Marketing, V.P. and General Manager API manufacturing and R&D. He also served as President of the Fine Chemicals and Pharmaceuticals Group at Cambrex Corporation.

    For further information, contact:

    Dr. Rudi E. Moerck, President and CEO
    Voice: 210-632-0695
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
2. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
3. Margaret Laub Appointed to IntelliDOT Board of Directors
4. Laurence Debroux Appointed Chief Strategic Officer (CSO)
5. Jean-Pierre Lehner Appointed Chief Medical Officer
6. Alice Stollenwerk Petrulis, MD, FACP, Appointed to NQF Care Coordination Committee
7. Former Assistant Secretary for Aging, The Honorable Josefina G. Carbonell, Appointed Senior Vice President at Independent Living Systems
8. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
9. Asthma & Allergy Foundation CEO Appointed to NIH Council
10. Ad de Waard Appointed Vice President of International Sales and Marketing at Accumetrics, Inc.
11. Latino Psychologist Appointed to Mental Health Post in Commonwealth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
(Date:5/23/2017)... ... 23, 2017 , ... The Gallery of Cosmetic Surgery, founded ... to announce a new treatment option called Vivace Microneedling. This treatment option is ... body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, best-in-class ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... video chat as a standard feature on its secure clinical communication platform. The ... voice to video depending on the type and urgency of a situation. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... treatment using the SPEED System™ Orthodontics, with or without a referral, from the ... in El Segundo, CA, who is skilled in providing patients with the custom, ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
Breaking Medicine Technology: